Last updated: October 11, 2026
Epacadostat is a discontinued oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor developed by Incyte. Its development failed after the Phase 3 ECHO-301/KEYNOTE-252 trial showed that epacadostat combined with pembrolizumab did not improve progression-free survival or overall survival in advanced melanoma. Incyte stopped the program in April 2018, and epacadostat has no FDA approval, no Orange Book listing, no marketed revenue, and no established generic-entry timetable.[1][2]
The commercial forecast is therefore zero under the current status quo. A market could reopen only if a new sponsor generated convincing clinical evidence in a biomarker-defined population or a different combination regimen. No such regulatory path has been established publicly.
What is the current development status of epacadostat?
Epacadostat, also known as INCB024360, is an oral small-molecule inhibitor of IDO1. IDO1 catalyzes tryptophan degradation and was investigated as an immune-suppression mechanism within the tumor microenvironment.
Incyte advanced epacadostat through multiple combination studies, with pembrolizumab as the principal development partner. The program initially attracted substantial interest because early-stage studies reported responses in melanoma and other solid tumors when epacadostat was combined with checkpoint blockade.
The decisive study was ECHO-301/KEYNOTE-252, a randomized Phase 3 trial in previously untreated patients with unresectable or metastatic melanoma. The trial compared:
| Treatment arm |
Regimen |
| Experimental |
Epacadostat plus pembrolizumab |
| Control |
Pembrolizumab plus placebo |
The combination failed to improve the primary endpoint of progression-free survival and failed to demonstrate an overall-survival advantage. Incyte terminated the study and stopped development of epacadostat across its broad oncology program in 2018.[1][2]
Key development milestones
| Date |
Milestone |
| 2007-2008 |
Early patent filings covering IDO1 inhibitor chemistry and related uses |
| 2013-2016 |
Phase 1 and Phase 2 combination studies begin across solid tumors |
| February 2017 |
Incyte and Merck expand collaboration around epacadostat and pembrolizumab |
| April 2018 |
ECHO-301/KEYNOTE-252 fails; Incyte discontinues the Phase 3 program |
| 2018 onward |
Broad clinical development is halted |
| Current status |
No FDA approval and no active commercial product |
Why did the epacadostat Phase 3 program fail?
The central clinical problem was the inability of epacadostat to add measurable benefit to pembrolizumab in an unselected melanoma population.
The Phase 3 result challenged the assumption that IDO1 inhibition would reliably reverse tumor-associated immune suppression. Several factors may have contributed:
- IDO1 activity may not have been sufficiently elevated in the enrolled tumors.
- Tumors may have used alternative tryptophan-catabolism pathways, including TDO2 or IDO2.
- Pharmacodynamic inhibition may not have been adequate across the tumor microenvironment.
- Earlier response signals may have reflected pembrolizumab activity rather than the contribution of epacadostat.
- The trial design did not require a validated biomarker indicating dependence on IDO1 biology.
The failure had broader consequences for the IDO1 field. Several other IDO1 programs were reduced or discontinued after ECHO-301, including efforts involving navoximod and other investigational inhibitors. The result reduced confidence in IDO1 as a general-purpose checkpoint-combination target.
What is the FDA regulatory status of epacadostat?
Epacadostat has no FDA approval and has not received an FDA regulatory designation that created commercial exclusivity.
| FDA issue |
Status |
| Approved indication |
None |
| New drug application |
No approval |
| Biologic license application |
Not applicable |
| FDA-approved label |
None |
| FDA orphan-drug exclusivity |
None publicly established |
| New chemical entity exclusivity |
None, because the drug was never approved |
| Priority review |
None |
| Accelerated approval |
None |
| Commercial launch |
None |
Clinical-trial participation did not create FDA marketing exclusivity. Because epacadostat never reached approval, it also did not receive the five-year new chemical entity exclusivity period available to an approved new active ingredient.
What is the Orange Book status of epacadostat?
Epacadostat has no FDA Orange Book listing because the product was never approved. As a result:
- No approved product reference is listed.
- No Orange Book patent certifications apply.
- No Paragraph IV challenge has been required against an approved epacadostat product.
- No 30-month stay has been triggered under the Hatch-Waxman framework.
- No generic applicant has a standard ANDA pathway against a marketed epacadostat reference product.
This distinction matters. Patent applications may have protected epacadostat chemistry or clinical uses, but those patents did not create Orange Book-listed barriers without an approved drug product.
What patents protect epacadostat?
Epacadostat was developed under Incyte’s IDO1 inhibitor patent program. The relevant intellectual-property categories included:
- Composition-of-matter patents covering substituted heterocyclic IDO1 inhibitors.
- Pharmaceutical-composition patents covering oral dosage forms.
- Method-of-treatment claims covering cancer and immune-related conditions.
- Combination-treatment claims involving checkpoint inhibitors.
- Potential process and intermediate claims related to chemical manufacture.
Public patent families associated with epacadostat were filed principally during the late 2000s and early 2010s. The core chemical patent term would generally run about 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers, prosecution history, and jurisdiction-specific rules.
Estimated patent timing
| Patent category |
Typical filing period |
General term outlook |
| Core compound and IDO1 inhibitor families |
2007-2008 |
Approximately 2027-2029 before any adjustment |
| Formulation and dosage-form families |
2009-2014 |
Approximately 2029-2034 |
| Method-of-use and combination families |
2010-2017 |
Approximately 2030-2037 |
| Manufacturing and process families |
2009-2016 |
Approximately 2029-2036 |
These ranges are not equivalent to enforceable expiry dates for a specific patent. Terminal dates depend on the exact patent family, national grant, patent-term adjustment, disclaimer history, maintenance fees, and claim scope.
What formulations are protected by epacadostat patents?
Epacadostat was developed as an oral small molecule, so the commercially relevant formulation strategy centered on solid oral dosage forms, most likely tablets or capsules. The relevant patent categories could include:
- Immediate-release oral tablets.
- Capsules containing crystalline or amorphous active ingredient.
- Salt, polymorph, solvate, or particle-size forms.
- Excipients and dissolution profiles.
- Dose-ranging regimens for combination therapy.
Because epacadostat never received approval, there is no FDA-approved commercial formulation whose composition is listed in the Orange Book. Formulation patents, if still enforceable, would operate as ordinary patent rights rather than as regulatory listing-based barriers.
What method-of-use patents cover epacadostat?
The clinical program generated potential method-of-use coverage in several areas:
- Treatment of melanoma.
- Treatment of non-small-cell lung cancer.
- Treatment of renal-cell carcinoma.
- Treatment of head and neck cancer.
- Treatment of colorectal and other solid tumors.
- Combination treatment with pembrolizumab.
- Combination treatment with nivolumab or other immune checkpoint inhibitors.
- Use in patients selected by IDO1 expression or related immune biomarkers.
Method-of-use claims have limited commercial value when the underlying drug has no approved indication. They may still matter in licensing, research use, or a future revival, but they do not create an active commercial monopoly without regulatory approval and an enforceable product or indication claim.
Which companies challenged epacadostat, and what litigation exists?
No major generic Paragraph IV litigation is associated with epacadostat because no approved reference product exists.
The main commercial legal event was not patent litigation. It was the Incyte-Merck clinical collaboration involving epacadostat and pembrolizumab. The agreement reflected the commercial expectations surrounding the program before the Phase 3 failure.
Publicly reported terms included:
| Collaboration element |
Reported position |
| Parties |
Incyte and Merck |
| Principal assets |
Epacadostat and pembrolizumab |
| Upfront payment |
$300 million reported by Merck and Incyte |
| Potential milestone value |
Up to approximately $5.5 billion reported |
| Strategic purpose |
Joint development of checkpoint-inhibitor combinations |
| Outcome |
Commercial thesis impaired after ECHO-301 failure |
The failed trial eliminated the near-term rationale for a large commercial launch. No settlement agreement involving generic entry is associated with epacadostat.
How strong is the epacadostat patent estate?
The patent estate was likely strongest during the period in which Incyte expected to commercialize epacadostat as a first-in-class IDO1 inhibitor. Its strongest assets would have been composition-of-matter claims that covered the active molecule itself or close chemical analogues.
Its current commercial strength is substantially lower for four reasons:
- The drug has no approved product.
- The primary clinical program was discontinued.
- Patent expiry for early chemical families is approaching or may already be partially eroded by prosecution and term limitations.
- Method-of-use patents have limited practical value without a validated clinical indication.
The estate could still create a manufacturing or licensing barrier if a future sponsor revived epacadostat. It would not, however, support a conventional branded-product forecast without new clinical data.
What is the market projection for epacadostat?
The base-case market projection is zero through the medium term because there is no active development program, regulatory filing, or commercial launch plan.
Market scenarios
| Scenario |
Probability profile |
Commercial outcome |
| Base case: continued discontinuation |
Highest based on public status |
No revenue and no market |
| Academic or investigator-led revival |
Low |
Limited clinical-use supply, no meaningful product revenue |
| Biomarker-selected oncology revival |
Low |
Potential niche launch after new Phase 2/3 evidence |
| Broad checkpoint-combination revival |
Very low |
Large theoretical market, but requires a new clinical thesis |
| Licensing to a new sponsor |
Low |
Asset value depends on patent life and proof-of-mechanism data |
A successful revival would require more than a new combination. The sponsor would likely need evidence that identifies patients with active IDO1 biology, confirms target inhibition in tumors, and demonstrates a clinically meaningful benefit over contemporary checkpoint therapy.
Theoretical market opportunity
Before the Phase 3 failure, the theoretical market included melanoma and multiple solid tumors treated with checkpoint inhibitors. That market was large because pembrolizumab and related drugs were used across several cancer indications. The commercial opportunity was therefore potentially substantial, but it depended on epacadostat adding incremental efficacy to an already successful immunotherapy platform.
That assumption was not validated. The addressable market should not be confused with forecast revenue. The current forecast is:
| Metric |
Current projection |
| Approved indications |
0 |
| Annual product sales |
$0 |
| FDA-approved competitors |
Not applicable |
| Generic sales |
$0 |
| Biosimilar sales |
Not applicable |
| Licensing revenue from a marketed product |
$0 |
| Near-term launch probability |
Very low |
How does epacadostat compare with competing IDO1 inhibitors?
Epacadostat was one of the most advanced IDO1 inhibitors, but its failure weakened the entire mechanism.
| Drug |
Sponsor |
Development position |
| Epacadostat |
Incyte |
Phase 3 failure; program discontinued |
| Navoximod |
Roche/Genentech |
Development curtailed after limited efficacy |
| Linrodostat |
Bristol Myers Squibb |
IDO1 program not established as a commercial product |
| Other IDO1 inhibitors |
Multiple sponsors |
Mostly early-stage, discontinued, or inactive |
Epacadostat’s competitive advantage was its clinical maturity and high-profile pembrolizumab combination. Its disadvantage became the same clinical result: the Phase 3 failure provided the strongest available evidence against broad IDO1 inhibition in melanoma.
What generic launch risks exist for epacadostat?
There is no immediate generic launch risk because no approved epacadostat product exists.
If a sponsor revived the molecule and obtained approval, the risk profile would depend on:
- Remaining composition-of-matter patent life.
- Validity and scope of formulation claims.
- Method-of-use patents for the approved indication.
- Whether the product received new chemical entity exclusivity through a new regulatory strategy.
- Whether a generic could design around formulation or process claims.
- The number and strength of patent families still enforceable in the United States, Europe, Japan, and other markets.
A future generic could face ordinary patent litigation, but there is no current ANDA competition or Paragraph IV timetable.
What is the geographic coverage of epacadostat intellectual property?
Incyte’s global development strategy required patent protection in major oncology markets, including the United States, Europe, Japan, and other jurisdictions with substantial pharmaceutical sales. International patent families generally provide a patchwork of national rights rather than one global patent.
The practical geographic value of the estate is limited by the lack of an approved product. Patent protection in a jurisdiction does not produce revenue unless the sponsor has:
- Regulatory approval.
- Commercial supply.
- Reimbursement access.
- A clinically differentiated indication.
- Enforceable claims extending beyond the likely launch date.
Key Takeaways
- Epacadostat is an investigational IDO1 inhibitor developed by Incyte.
- The Phase 3 ECHO-301/KEYNOTE-252 trial failed in advanced melanoma.
- Incyte discontinued the broad development program in 2018.
- Epacadostat has no FDA approval, no Orange Book listing, and no approved exclusivity period.
- No Paragraph IV litigation or generic launch timetable exists.
- The patent estate likely includes composition, formulation, method-of-use, combination, and manufacturing families.
- Early chemical patent families were generally filed around 2007-2008, placing their ordinary term near 2027-2029 before adjustments.
- The current commercial forecast is zero.
- A future market would require a new sponsor, biomarker validation, renewed clinical development, and regulatory approval.
- The former Incyte-Merck collaboration created a large theoretical opportunity, but the Phase 3 failure removed the near-term commercial case.
FAQs
Is epacadostat still being developed?
No active broad commercial development program has been publicly established after Incyte discontinued the program following the 2018 ECHO-301 failure.
Can epacadostat be prescribed in the United States?
No. Epacadostat is not FDA-approved and is not available as an approved prescription medicine.
Does epacadostat have a biosimilar risk?
No. Epacadostat is a small molecule, not a biologic. The relevant future competition would be generic-drug competition, not biosimilar competition.
Could epacadostat return through a new cancer indication?
Technically, a new sponsor could restart development, but it would need new clinical evidence. The most credible strategy would likely involve biomarker-selected patients and a differentiated immune-combination mechanism.
What is the investment value of epacadostat today?
The asset has limited standalone commercial value without an active sponsor, clinical program, regulatory filing, or validated biomarker strategy. Any residual value would primarily arise from surviving patent rights, know-how, clinical data, and the possibility of out-licensing or research use.
References
- Incyte Corporation. (2018, April 6). Incyte announces top-line results from Phase 3 ECHO-301/KEYNOTE-252 study of epacadostat in combination with pembrolizumab.
- Long, G. V., et al. (2019). Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: The Phase 3 ECHO-301/KEYNOTE-252 study. Journal of Clinical Oncology, 37(8), 647-656.
- Merck & Co., Inc. (2017, February 6). Merck and Incyte announce collaboration to evaluate epacadostat in combination with KEYTRUDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- ClinicalTrials.gov. (2018). ECHO-301/KEYNOTE-252: Epacadostat plus pembrolizumab versus pembrolizumab alone in advanced melanoma. National Library of Medicine.